UK Markets closed

Achilles Therapeutics plc (ACHL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.0700+0.0200 (+0.49%)
At close: 04:00PM EST
4.0700 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.2600
Open4.2200
Bid0.0000 x 1200
Ask0.0000 x 800
Day's range4.0900 - 4.4200
52-week range4.0200 - 18.9480
Volume68,998
Avg. volume165,874
Market cap165.256M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.8840
Earnings date09 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.50
  • Globe Newswire

    Achilles Therapeutics Provides Business Update and Outlook for 2022

    LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces a business update and reflects on recent progress with its pioneering, personalized T cell therapy programs targeting clonal neoantigens known as cNeT. As the original mutations formed early in cancer’s development, clonal neoantigens are protein markers that are present on all of an individual’

  • Simply Wall St.

    Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • Globe Newswire

    Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

    LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET. A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website. About